The Indian pharmaceutical industry positions among the top five countries by volume (production) and accounts for about 10% of worldwide production. The industry's gross revenue has grown from a simple US$ 0.3 bn in 1980 to about US$ 21.73 billion in 2009 
INTRODUCTION
The narration of the progress of the Indian pharmaceutical industry can be alienated into four principal eras. The first era is from 1850 to 1945. The second age spans from 1945 to the late 1970s. The third era for development is from the early 1980s to the early 1990s, and the fourth epoch extents from the early 1990s to the present time.
The Premature Stage of Pharmaceutical Evolution
For ease, the early on stage of Pharmaceutical evolution has been divided into two distinctive phases viz., the pre-independence and the post independence developments.
Pre-Independence Situation
Before the arrival of British Rule, the original forms of medicine were in use (Ayurrvedic or Unani) in India. The Central Government of British India first presented the allopathic form of medicine in the nation. However, there were no manufacture units in the country. Instead, the foreign companies exported raw materials from India, transformed it into finished products, and imported it reverse to India (Chaudhuri 1984) 1 . In spite of genuine hard work by a handful number of entrepreneurs to set up native companies, drug manufacture in the country was little and could barely meet only 13% of the total medicinal necessity of the country. The original industry, however, received force during the Second World War due to the fall in the deliver of drugs from overseas companies and many more Indian companies like Unichem, Chemo Pharma, Zandu
Pharmaceutical Works, Calcutta Chemicals, Standard Chemicals, Chemical Industrial and Pharmaceutical Laboratories (now known as Cipla), East India Pharmaceutical Works and others were established. With the entrance of fresh firms in the market the making of drugs improved rapidly and indigenous firms were competent to satisfy about 70% of the country"s medicinal obligation. During this stage, overseas companies across the globe as well as Indian companies were busy in production connected activities and the importance of R&D was strange to them (Temin, 1976). Whichever novel inventions of drugs were made were largely owing to the individual efforts of scientists and the drug companies were not concerned in it (Chaudhuri 2005).
Post Independence Picture
The era spans from 1945 to roughly the mid 1970s. A major advance known as therapeutic revolution noticeable the beginning of this period and stemmed in a phenomenal growth of the global pharmaceutical industry situated mainly in Germany, Switzerland, the UK and also to some extent in the US. A notable accomplishment during this era was a transfer in drug therapy from treating the symptoms to treating the disease itself (Temin, 1976) . At the same time there was a significant shift in the structure of the industry mainly because the global pharmaceutical industry instead of being mere production units also embarked on the path of massive investment in R&D Furthermore, India"s share in the global GDP has been gradually increasing, and is expected to reach 6.28% in 2015, up from 4.17% in 2005.
Rise of Middle Class with Higher Purchasing Power
India"s population is currently just over 1.1 billion and is predictable to rise to 
Changing Disease Contour
The Indian population is experiencing a swing in disease profiles (Figure) . Conventionally, the acute disease slice held a major share of the Indian pharmaceutical market. This segment will carry on to breed at a solid rate, due to issues unfolding to public hygiene and sanitation. But, with boost in affluence, rise in life expectancy and the onset of lifestyle associated conditions, the disease profile is slowly shifting towards a enlargement in the chronic diseases segment. India has the largest group of diabetic patients in the world, with more than 41 million people suffering from the disease; this is projected to reach 73.5 million in 2025.
The growing dimension of the Indian geriatric population will be a major factor in influencing the growth of the chronic segment. By 2028, an projected 199 million Indians will be age 60 or 
Government Policies
The Indian government has been making efforts to get better countrywide provision of healthcare. It has launched policies that are intended at:
• constructing more hospitals,
• boosting home access to healthcare,
• getting better the quality of medical education,
• escalating public expenditure on healthcare to 2-3% of GDP, up from a current low of 1%.
The government, along with numerous in the industry believes that increase in insurance coverage is vital to take the market forward. But, other experts believe that the extent of health insurance could lead to a market wherein there is negligible differentiation between branded generics. An essential success factor for generic makers is separation of their products. While increased health insurance coverage may benefit generic drug manufacturers by increasing the market"s affordability for medicines, it may, in combination with increased institutional sales cause a reduction in prices, owing to the rising influence of insurance companies.
Overall, dearth of insurance coverage still leftovers a challenge. Widespread use of health insurance could take many ages, not least because insurance companies lack the data they require to measure health risks precisely and the only products they sell graft on an indemnity basis -that is, they compensate the patient after he or she has paid the healthcare provider"s bill, making such policies less eye-catching. 
KASHMIR ASPECT

Protection of Medicinal Plants
In-situ Conservation is usually the favoured conservation plan for capturing and conserving
Medicinal Plant pockets in their natural habitats. Stress is laid on recognition of Medicinal Plant areas having rich biodiversity of genetic resources that have main concern, usually at the species level on the basis of current or potential socio-economic value of the species and their conservation importance in the ecosystem along with group of its associate species. The area-specific action plan and networking of natural sites has to be measured to be the most important aspects of in-situ conservation activities. The ecological necessity of many of the species is multipart. Hence moving them out of their own area of comfort to fresh area may for a while prove counterproductive.
Hence by recuperating the protection, removing all kind of threats is one of the vital steps towards insitu conservation. Conservation units are not kept too small because this will cause unremitting loss of genetic diversity by the things of genetic drift and increased inbreeding. Considering this, the area has got to be large enough for maintaining the genetic integrity of the original inhabitants and for generating enough germ production. Some of the reserves like Achabal Conservation
Reserve (Rakh) have dense forests and are denser compared to close compartments/forests.
The scientific management of forests can offer enabling environment for the medicinal plant species to prosper. It involves awning handling to provide light, governing of other unwanted species, control of Invasive species, removal of humus to provide ground contact to seeds of medicinal plants, soil and moisture conservation works to prevent soil erosion and to improve soil moisture regime etc. Enabling environment also involves achievement the public support for the protection. As forest reliant communities are major stakeholders, it is very imperative that they get the benefit out of medicinal plant conservation programmes. Providing job opportunities and sharing economic profits with JFMCs can definitely help.
Ex-Situ Conservation of Medicinal Plants
Ex-situ conservation involves the procedure of protecting rare species and developing it remote its natural habitat. For medicinal plants, Ex-situ Conservation aims at the preservation concern by way of raising of nurseries, seedling supply, plantations and by establishing medicinal plant gardens. Establishment and Management of Ex-situ Conservation stands requires the total information of the forest trees, shrubs and herbs which have developed complex mechanism to uphold high level of genetic diversity, both inter-specific and intra-specific . It provides the structure blocks for future evolution, selection and human use in within and among populations of target species. It includes each simple seed collection, storage and field plantings or more rigorous plant breeding and development approaches. The vital aspect of ex-situ conservation is to uphold a broad range of phenotypic and genotypic range of diversity of a species and to spread the species outside its original natural provenance in a more guarded way. The choice of species for ex-situ conservation is made on the basis of the present local significance of the species, economic value for the subsistence of local population, ecological and geographic considerations and capacity for natural regeneration and the current protection status.
CHALLENGES
Price Controls
Price controls are generally cited as the most important challenge that companies face in the Indian market. India is one of the most price-controlled markets in the sphere, as under the DPCO, prices and margins are monitored sensibly. Price controlled drugs are vital medicines, such as antibiotics and painkillers, and drugs used for the treatment of diseases such as cancer and asthma.
However, 90% of drugs are currently outside of any price controls in India. Consumer organizations uphold their stance of influence the government to carry on to expand the umbrella of the DPCO, but the industry believes that there is sufficient competition for the prices to be moderated by the market itself.
Infrastructure
Infrastructure has for all time been mentioned as a barrier to growth of the Pharma industry in India. Poor oomph and transport infrastructure has traditionally posed a difficulty for companies.
Some areas lack elementary hotel facilities, preventing reach and infiltration. With the government gradually growing investment in infrastructure, the situation is taming, but it is still seen as an investment break in India.
Counterfeiting
Counterfeiting of drugs has been a key issue in the Indian Pharma freedom. The intrinsic nature of the Indian market makes it hard for a regular study that quantifies the extent of counterfeiting, to be carried out. There have been numerous reports telltale plentiful figures as the rate of counterfeiting. A good indicator may be a large scale survey that was published in December 2009 by the health ministry that reported that false drug prevalence is much lower than otherwise put forward. The report found that only 0.046% of all medicines sold contained indication of being bogus. These reports suggesting lower numbers than earlier ones may be hopeful, but leading players are still tired of the threat of spurious drugs. Steps taken by the industry to pledge the threat of counterfeiting comprise investing in innovative packaging, using authenticity markers and sponsoring programmes to increase alertness amongst patients and healthcare workers.
Intellectual Property
India 
CONCLUSION
Kashmir can turn into a "hub for pharmaceutical industries in India." There is a huge potential for developing bio-pharmaceutical industry in the state, given its conducive investment climate.
Over 50 per cent of plant species described in British Pharmacopoeia were reported growing in Kashmir. Kashmir, is blessed with various medicinal plants that mostly grew on the mountains of the Valley, of which nearly 570 plant species were of huge medicinal importance. "Based on these high value plant species, Kashmir has a huge potential for establishing bio-pharmaceutical industry," adding that the herbal plants that were grown in Kashmir could not be replicated in other parts of the world.
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